Latest Headlines

  1. The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC) Makes Breakthroughs Break Through As Boreal Biomanufacturing 6/18/2026

    The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), a facility that has developed more than 20 distinct cell- and virus-based products for human clinical trials in Canada, the United States, Europe and Asia, is becoming Boreal Biomanufacturing (Boreal). 

  2. Minaris Enhances GMP Cell Banking Suites At Philadelphia Facility 6/18/2026

    Minaris, a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization, today announced the enhancement of its dedicated GMP cell banking suites at its Philadelphia facility, a centralized hub for cell banking and biosafety testing. 

  3. Recipharm Invests In U.S. Fill-Finish Infrastructure To Accelerate Biologics Development 6/17/2026

    Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharmaceutical and biotechnology companies with advanced sterile fill and finish services for biologics and advanced therapies.

  4. Annex 1 Is Not the Ceiling For Compliance; It Is The Foundation 6/11/2026

    The sterile manufacturing industry is undergoing a significant transformation as regulatory agencies shift towards a comprehensive approach to compliance. GRAM explores the implications of recent updates, such as those to Annex 1, that formed a framework for their compliance strategies through proactive contamination control, risk management, and transparency.

  5. Rezon Bio Appoints Dr. Ralf Otto As Chief Operating Officer To Support Next Phase Of Growth And Operational Expansion 6/3/2026

    Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Ralf Otto, as Chief Operating Officer (COO) effective June 1, 2026.

  6. Leica Biosystems And CellCarta Expand Collaborative Companion Diagnostic Development Model To Accelerate Commercialization Globally 6/1/2026
  7. Andelyn Biosciences Establishes The Andelyn Foundation To Support Families Living With Rare And Ultra-Rare Diseases 5/29/2026

    Andelyn Biosciences Inc., a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the unveiling of The Andelyn Foundation, a nonprofit organization dedicated to supporting families living with rare and ultra-rare diseases through awareness, fundraising, and compassionate community engagement.

  8. Andelyn Biosciences Launches LVV Curator® Platform, Bringing Proven Viral Vector Platform Pedigree To Lentiviral Vector Manufacturing For Cell Therapies 5/29/2026

    Andelyn Biosciences, a leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced the launch of its LVV Curator® Platform, a standardized lentiviral vector (LVV) manufacturing solution built on the same proven modular approach that supports clinical and commercial adeno-associated virus (AAV) programs.

  9. Andelyn Biosciences Receives Dark Horse Consulting Certification Of Gene Therapy Manufacturing Systems And Capabilities Within Its Initiative For Certification Of Manufacturing Capabilities (ICMC™) Program 5/29/2026

    Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced it has received full certification under the Initiative for Certification of Manufacturing Capabilities (ICMC) program from Dark Horse Consulting, recognizing the company’s capability to support advanced therapies manufacturing with its quality and production systems.

  10. AGC Biologics To Manufacture Teikoku Seiyaku's rhMMP-7 Drug Substance 5/28/2026

    AGC Biologics to provide process development and GMP manufacturing for a novel therapy, leveraging its global microbial network across Germany and Japan.